US › Healthcare

Unicycive Therapeutics Inc (UNCY)

US · Healthcare · Biotechnology

$3.36-6.41%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-1.7M

EPS

$-0.06

EPS estimate

$-0.34

EPS came in at -0.06 against a street estimate of -0.34 — a beat of 82.4%.

Key statistics

Market cap

$112.6M

Forward P/E

1.5

P/B

2.52

Book value

$1.91

EPS (TTM)

$-1.72

52-week high

$8.74

52-week low

$3.93

50-day MA

$5.03

200-day MA

$6.28

Beta

1.82

Analyst view

Analysts rate Unicycive Therapeutics Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $28.40.

Shareholding

Insiders

2.26%

Institutions

42.27%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	10.06%
BlackRock Inc	5.07%
Vanguard Capital Management, LLC	3.85%
Octagon Capital Advisors LP	3.59%
Geode Capital Management, LLC	2.02%
Vivo Capital, LLC	1.97%
Marshall Wace Asset Management Ltd	1.97%
Logos Global Management LP	1.70%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Unicycive Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.